Hostname: page-component-6587cd75c8-h2j7s Total loading time: 0 Render date: 2025-04-23T14:39:42.716Z Has data issue: false hasContentIssue false

Poison Pills in the Shadow of the Law

Published online by Cambridge University Press:  07 April 2025

K. J. Martijn Cremers*
Affiliation:
Mendoza College of Business, University of Notre Dame
Simone M. Sepe
Affiliation:
Faculty of Law and Rotman School of Management, University of Toronto [email protected]
Michal Zator
Affiliation:
Mendoza College of Business, University of Notre Dame [email protected]
Lubomir P. Litov
Affiliation:
Price College of Business, University of Oklahoma [email protected]
*
[email protected] (corresponding author)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Poison pills are among the most powerful antitakeover provisions, but studying their economic impact is challenging because of the obvious endogeneity concerns. We address the problem by studying U.S. states’ staggered adoption of poison pill laws (PPLs), which strengthen the right to adopt a pill (i.e., the shadow pill) and increase the validity of visible pills. We document that PPLs make visible pill policy aligned with economic incentives, increasing pill adoption among firms with a high likelihood of takeover, but decreasing it among firms with low takeover likelihood. We also document that PPLs positively impact firm value, especially for innovative firms with more intangible assets.

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of the Michael G. Foster School of Business, University of Washington

References

Acharya, V. V.; Baghai, R. P.; and Subramanian, K. V.. “Wrongful Discharge Laws and Innovation.” Review of Financial Studies, 27 (2014), 301346.CrossRefGoogle Scholar
Ambrose, B. W., and Megginson, W. L.. “The Role of Asset Structure, Ownership Structure, and Takeover Defenses in Determining Acquisition Likelihood.” Journal of Financial and Quantitative Analysis, 27 (1992), 575590.CrossRefGoogle Scholar
Angrist, J. D., and Pischke, J. S.. “Mostly Harmless Econometrics: An Empiricist’s Companion.” 1st Ed. (2009) (Princeton, NJ: Princeton University Press).CrossRefGoogle Scholar
Atanassov, J.Do Hostile Takeovers Stifle Innovation? Evidence from Antitakeover Legislation and Corporate Patenting.” Journal of Finance, 68 (2013), 10971131.Google Scholar
Baker, A.; Larcker, D.; and Wang, C.. “How Much Should We Trust Staggered Difference-In-Differences Estimates?Journal of Financial Economics, 144 (2022), 370395.CrossRefGoogle Scholar
Bebchuk, L. A.; Cohen, A.; and Ferrell, A.. “What Matters in Corporate Governance?Review of Financial Studies, 22 (2009), 783827.CrossRefGoogle Scholar
Bizjak, J. M., and Marquette, C. J.. “Are Shareholder Proposals All Bark and No Bite? Evidence from Shareholder Resolutions to Rescind Poison Pills.” Journal of Financial and Quantitative Analysis, 33 (1998), 499521.CrossRefGoogle Scholar
Brickley, J. A.; Coles, J. L.; and Terry, R. L.. “Outside Directors and the Adoption of Poison Pills.” Journal of Financial Economics, 35 (1994), 371390.Google Scholar
Cain, M. D.; McKeon, S. B.; and Solomon, S. D.. “Do Takeover Laws Matter? Evidence from Five Decades of Hostile Takeovers.” Journal of Financial Economics, 124 (2017), 464485.CrossRefGoogle Scholar
Callaway, B., and Sant’Anna, P.. “Difference-in-Differences with Multiple Time Periods.” Journal of Econometrics, 225 (2021), 200230.CrossRefGoogle Scholar
Carhart, M. M.On Persistence in Mutual Fund Performance.” Journal of Finance, 52 (1997), 5782.CrossRefGoogle Scholar
Catan, E. M.The Insignificance of Clear-Day Poison Pills.” Journal of Legal Studies, 48 (2019), 144.Google Scholar
Catan, E.M., and Kahan, M.. “The Law and Finance of Antitakeover Statutes.” Stanford Law Review, 68 (2016), 629682.Google Scholar
Caton, G. L., and Goh, J.. “Corporate Governance, Shareholder Rights, and Shareholder Rights Plans: Poison, Placebo, or Prescription?Journal of Financial and Quantitative Analysis, 43 (2008), 381400.CrossRefGoogle Scholar
Coates, J.Takeover Defenses in the Shadow of the Pill: A critique of the Scientific Evidence.” Texas Law Review, 79 (2000), 271382.Google Scholar
Cohen, A., and Wang, C. C.. “How Do Staggered Boards Affect Shareholder Value? Evidence from a Natural Experiment.” Journal of Financial Economics, 110 (2013), 627641.CrossRefGoogle Scholar
Comment, R., and Schwert, G. W.. “Poison or Placebo? Evidence on the Deterrence and Wealth Effects of Modern Antitakeover Measures.” Journal of Financial Economics, 39 (1995), 343.CrossRefGoogle Scholar
Cotter, J. F.; Shivdasani, A.; and Zenner, M.. “Do Independent Directors Enhance Target Shareholder Wealth During Tender Offers?Journal of Financial Economics, 43 (1997), 195218.CrossRefGoogle Scholar
Cremers, K. J. M., and Ferrell, A.. “Thirty Years of Shareholder Rights and Firm Value.” Journal of Finance, 69 (2014), 11671196.CrossRefGoogle Scholar
Cremers, K. J. M.; Litov, L. P., and Sepe, S. M.. “Staggered Boards and Long-Term Firm Value, Revisited.” Journal of Financial Economics, 126 (2017), 422444.CrossRefGoogle Scholar
Cremers, K. J. M.; Nair, V. B.; and John, K.. “Takeovers and the Cross-Section of Returns.” Review of Financial Studies, 22 (2009), 14091445.CrossRefGoogle Scholar
Cremers, K. J. M., and Sepe, S. M.. “The Shareholder Value of Empowered Board.” Stan. L. Rev. 68 (2016), 67148.Google Scholar
Cuñat, V.; Gine, M.; and Guadalupe, M.. “The Vote is Cast: The Effect of Corporate Governance on Shareholder Value.” Journal of Finance, 67 (2012), 19431977.CrossRefGoogle Scholar
Danielson, M. G., and Karpoff, J. M.. “Do Pills Poison Operating Performance?Journal of Corporate Finance, 12 (2006), 536559.CrossRefGoogle Scholar
Datta, S., and Iskandar-Datta, M.. “Takeover Defenses and Wealth Effects on Security Holders: The Case of Poison Pill Adoptions.” Journal of Banking and Finance, 20 (1996), 12311250.CrossRefGoogle Scholar
DeAngelo, H., and Rice, E. M.. “Antitakeover Charter Amendments and Stockholder Wealth.” Journal of Financial Economics, 11 (1983), 329359.CrossRefGoogle Scholar
Edmans, A.; Goldstein, I.; and Jiang, W.. “The Real Effects of Financial Markets: The Impact of Prices on Takeovers.” Journal of Finance, 67 (2012), 933971.Google Scholar
Fama, E. F., and French, K. R.. “The Cross‐Section of Expected Stock Returns.” Journal of Finance, 47 (1992), 427465.Google Scholar
Fama, E. F., and French, K. R.. “Common Risk Factors in the Returns on Stocks and Bonds.” Journal of Financial Economics, 33 (1993), 356.CrossRefGoogle Scholar
Field, L. C., and Karpoff, J. M.. “Takeover Defenses of IPO Firms.” Journal of Finance, 57 (2002), 18571889.Google Scholar
Fleischer, A. and Sussman, A.. Takeover Defenses. New York: Aspen Law and Business (2013).Google Scholar
Gillan, S. L., and Starks, L. T.. “Corporate Governance Proposals and Shareholder Activism: The Role of Institutional Investors.” Journal of Financial Economics, 57 (2000), 275305.CrossRefGoogle Scholar
Giroud, X., and Mueller, H. M.. “Does Corporate Governance Matter in Competitive Industries?Journal of Financial Economics, 95 (2010), 312331.CrossRefGoogle Scholar
Gompers, P.; Ishii, J.; and Metrick, A.. “Corporate Governance and Equity Prices.” Quarterly Journal of Economics, 118 (2003), 107156.CrossRefGoogle Scholar
Gormley, T. A., and Matsa, D. A.. “Growing Out of Trouble? Corporate Responses to Liability Risk.” Review of Financial Studies, 24 (2011), 27812821.CrossRefGoogle Scholar
Gormley, T. A., and Matsa, D. A.. “Playing It Safe? Managerial Preferences, Risk, and Agency Conflicts.” Journal of Financial Economics, 122 (2016), 431455.CrossRefGoogle Scholar
Hart, O., and Moore, J.. “Property Rights and the Nature of the Firm.” Journal of Political Economy, 98 (1990), 11191158.CrossRefGoogle Scholar
Heath, D.; Macciocchi, D.; Michaely, R.; and Ringgenberg, M. C.. “Do Index Funds Monitor?Review of Financial Studies, 35 (2022), 91131.CrossRefGoogle Scholar
Henderson, J. V., and Ono, Y.. “Where Do Manufacturing Firms Locate Their Headquarters?Journal of Urban Economics, 63 (2008), 431450.CrossRefGoogle Scholar
Heron, R. A., and Lie, E.. “On the Use of Poison Pills and Defensive Payouts by Takeover Targets.” Journal of Business, 79 (2006), 17831807.CrossRefGoogle Scholar
Heron, R. A., and Lie, E.. “The Effect of Poison Pill Adoptions and Court Rulings on Firm Entrenchment.” Journal of Corporate Finance, 35 (2015), 286296.CrossRefGoogle Scholar
Jensen, M.C., and Meckling, W. H.. “Theory of the Firm: Managerial Behavior, Agency Costs and Ownership Structure.” Journal of Financial Economics, 3 (1976), 305360.CrossRefGoogle Scholar
Johnson, W. C.; Karpoff, J. M.; and Yi, S.. “The Bonding Hypothesis of Takeover Defenses: Evidence from IPO Firms.” Journal of Financial Economics, 117 (2015), 307332.CrossRefGoogle Scholar
Kadyrzhanova, D., and Rhodes-Kropf, M.. “Concentrating on Governance.” Journal of Finance, 66 (2011), 16491685.Google Scholar
Karpoff, J. M., and Malatesta, P. H.. “The Wealth Effects of Second-Generation State Takeover Legislation.” Journal of Financial Economics, 25 (1989), 291322.CrossRefGoogle Scholar
Karpoff, J. M., and Wittry, M. D.. “Institutional and Legal Context in Natural Experiments: The Case of State Antitakeover Laws.” Journal of Finance, 73 (2018), 657714.CrossRefGoogle Scholar
Klausner, M.Fact and Fiction in Corporate Law and Governance.” Stanford Law Review, 65 (2013), 1325.Google Scholar
Knott, A. M.R&D Returns Causality: Absorptive Capacity or Organizational IQ.” Management Science, 54 (2008), 20542067.CrossRefGoogle Scholar
Laffont, J., and Tirole, J.. “Repeated Auctions of Incentive Contracts, Investment and Bidding Parity, with an Application to Takeovers.” RAND Journal of Economics, 19 (1988), 516537.CrossRefGoogle Scholar
MacIntosh, J. G.The Poison Pill: A Noxious Nostrum for Canadian Shareholders.” Canadian Business Law Journal, 15 (1989), 276334.Google Scholar
Malatesta, P. H., and Walkling, R. A.. “Poison Pill Securities: Stockholder Wealth, Profitability, and Ownership Structure.” Journal of Financial Economics, 20 (1988), 347376.CrossRefGoogle Scholar
Peters, R. H., and Taylor, L. A.. “Intangible Capital and the Investment-q Relation.” Journal of Financial Economics, 123 (2017), 251272.CrossRefGoogle Scholar
Rhodes-Kropf, M.; Robinson, D. T.; and Viswanathan, S.. “Valuation Waves and Merger Activity: The Empirical Evidence.” Journal of Financial Economics, 77 (2005), 561603.CrossRefGoogle Scholar
Ryngaert, M.The Effect of Poison Pill Securities on Shareholder Wealth.” Journal of Financial Economics, 20 (1988), 377417.CrossRefGoogle Scholar
Shleifer, A. and Summers, L.. Breach of Trust in Hostile Takeovers in: ‘Corporate Takeovers: Causes and Consequences.’ The University of Chicago Press (1988).CrossRefGoogle Scholar
Stein, J. C.Takeover Threats and Managerial Myopia.” Journal of Political Economy, 96 (1988), 6180.CrossRefGoogle Scholar
Stein, J. C.Efficient Capital Markets, Inefficient Firms: A Model of Myopic Corporate Behavior.” Quarterly Journal of Economics, 104 (1989), 655669.CrossRefGoogle Scholar
Straska, M., and Waller, H. G.. “Antitakeover Provisions and Shareholder Wealth: A Survey of the Literature.” Journal of Financial and Quantitative Analysis, 49 (2014), 933956.CrossRefGoogle Scholar
Supplementary material: File

Martijn Cremers et al. supplementary material

Martijn Cremers et al. supplementary material
Download Martijn Cremers et al. supplementary material(File)
File 618.2 KB